Systemic sclerosis & Raynaud's
Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
Authors' conclusion
Our results suggest that HSCT favourably alters the autoantibody repertoire, which remains virtually unchanged in CTX-treated patients.
Study context
- Population
- Participants of the SCOT trial with SSc
- Comparison
- Haematopoietic stem cell transplant (HSCT) vs CTX
- Primary endpoint
- Serum IgG autoantibody profiles (hypothesis: transplantation stabilises the autoantibody repertoire in patients with favourable clinical outcomes)
Methodological detailsbead-based array of 221 protein antigens, linear mixed model analysis
- Bead-based array of 221 protein antigens
- Linear mixed model analysis
Primary result
As reported in the abstract
Autoantibody profiles · month 26
- Antibodies against two viral antigens and six self-proteins (SSB/La, CX3CL1, EJ, parietal cell antigen, bactericidal permeability-increasing protein, epidermal growth factor receptor (EGFR)) significantly different between treatment groups (n=23 HSCT; n=22 CTX)
- Temporal increases in antibody levels for hepatitis B surface antigen, CCL3 and EGFR in HSCT-treated patients (linear mixed model)
- Participants with temporally varying serum antibody profiles for ≥1 of 14 antigens: 8 of 32 HSCT vs 1 of 31 CTX
Further findings
Baseline autoantibody levels and event-free survival to month 54
- Baseline autoantibody levels against 20 unique antigens (incl. 9 secreted proteins: IL-18, IL-22, IL-23, IL-27, interferon-α2A, stem cell factor, TGF-β, M-CSF, macrophage migration inhibitory factor) significantly higher in patients who survived event-free to month 54
Original publication
Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation. Ann Rheum Dis. Published 18 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →